Pfizer and Arvinas gamble to shift breast cancer treatment paradigm
Pfizer's and Arvinas' vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) ER degrader. The drug exploits the ubiquitin-proteasome system, degrading the mutant ER complex and greatly slowing growth and increasing tumour survivability. As the drug drives degradation and more specific targeting than small-molecule ER inhibitor receptors in preclinical studies, this class could leave a more profound effect with a tolerable safety profile. In the Phase II VERITAC trial, the drug was well-tolerated in a heavily CDK4/6 inhibitor pre-treated BC patient setting. Of 35 patients receiving 200mg of vepdegestrant, there was only one discontinuation and no dose reductions.
A press release by Arvinas announced the results from the Phase III trial, VERITAC-2. Significant improvements to progression-free survival were seen with a hazard ratio of 0.60 in the ESR1m patient subpopulation for patients receiving vepdegestrant monotherapy compared to fulvestrant. This improvement was not seen in the overall population, including non-ESR1m patients. These patients had previously experienced progression following CDK4/6 inhibitor treatment. The full trial results are to be announced on 31 May at the 2025 American Society of Clinical Oncology conference.
While initial safety and efficacy results are positive, the recent controversy surrounding the efficacy of CDK4/6 inhibitors in improving overall survival for breast cancer patients will hurt sales and the growth of the market share accessible to vepdegestrant. Regardless, the projected impact of vepdegestrant is suspected to be strong for the ESR1m population, which currently affects up to 39% of endocrine-resistant metastatic BC cases. GlobalData's analyst consensus forecasts estimate the drug to reach $1.64 billion in sales for metastatic breast cancer by 2031.
"Pfizer and Arvinas gamble to shift breast cancer treatment paradigm" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
33 minutes ago
- Medscape
RSV Jab Shields Older Adults from Hospitalisation
The UK Health Security Agency (UKHSA) has reported that the respiratory syncytial virus (RSV) vaccine is around 82% effective in preventing hospitalisation among adults aged 75-79. The data come from a study run in partnership with Nottingham University Hospitals and other NHS trusts. UKHSA called the results 'strong protection'. The study used data from a hospital-based sentinel surveillance system covering 14 hospitals in England. It included adults admitted for acute respiratory infections between 1 October 2024 and 31 March 2025. Of 1006 adults hospitalised with acute respiratory infections (ARI), 173 (17.2%) had RSV infection. Vaccine Efficacy by Clinical Subgroup Data showed vaccine efficacy against hospitalisation of: 82.3% for any RSV-associated ARI 86.7% for severe cases needing oxygen supplementation 88.6% for lower respiratory tract infection, including pneumonia 77.4% for exacerbations of chronic lung disease 78.8% for exacerbations linked to chronic heart disease, lung disease, or frailty 72.8% for adults with immunosuppression Maternal RSV Vaccination Also Effective The UKHSA also reviewed data from the maternal RSV vaccination programme, introduced alongside the older adults programme in September 2024. A separate study, published in The Lancet Child & Adolescent Health , found the maternal RSV vaccine reduced infant hospitalisation risk by 72% when given more than 14 days before birth. Both programmes use Pfizer's bivalent pre-F vaccine, Abrysvo). The programme for older adults offers the vaccine to those turning 75, as well as a one-off catch-up campaign for all adults aged 75-79 years. The maternal programme offers the vaccine from 28 weeks of pregnancy. Uptake Rates Vary Across Groups By 30 June, uptake among eligible older adults had risen to 62.9%, up from 60.3% in March. Among 36,657 women who gave birth in March, 54.7% had received the RSV vaccine during pregnancy. Coverage in the maternal programme varied by ethnic group. Uptake Uptake ranged from 73.3% among women of Chinese ethnicity to 26.4% among Black and Black British Caribbean women. RSV Seasonality and Surveillance Findings RSV activity typically starts in October. Bronchiolitis, the main clinical presentation in infants, is primarily caused by risk of hospitalisation with RSV infection is highest among babies born in late summer or autumn. The UKHSA's first annual RSV report reviewed the 2024-2025 season. It found: RSV activity began around mid-October across all UK nations It peaked between 18 November and 8 December (weeks 47 to 49) It declined to baseline levels by late February (weeks 7-8 of 2025) Primary care surveillance included around 300 GP practices in England, which swab patients presenting with ARI. Peak RSV positivity was: 53.1% in children under 5 during week 46 (11-17 November) 18.5% in adults aged 75 and over during week 49 (2-8 December) Hospital emergency department data also showed that bronchiolitis in infants under 1 year peaked in late November. MHRA Warns of Guillain-Barré Syndrome Risk In July, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a drug safety alert on RSV vaccines. Clinicians are advised to monitor for symptoms of Guillain-Barré syndrome (GBS) following vaccination. GBS is an acute demyelinating disease affecting the peripheral nervous system. Early symptoms include tingling, numbness, or pins and needles in the feet and hands, followed by muscle weakness and difficulty moving joints. In some cases, it can progress to breathing difficulties, drooping facial muscles, problems with swallowing or speech, and double vision. Although rare, GBS can be fatal.
Yahoo
2 hours ago
- Yahoo
How To Earn $500 A Month From Pfizer Stock Ahead Of Q2 Earnings
Pfizer Inc. (NYSE:PFE) will release earnings results for the second quarter before the opening bell on Tuesday, Aug. 5. Analysts expect the pharmaceutical company to report quarterly earnings of 57 cents per share, down from 60 cents per share in the year-ago period. Pfizer projects to report quarterly revenue of $13.53 billion, compared to $13.28 billion a year earlier, according to data from Benzinga Pro. Some investors may be eyeing potential gains from the company's dividends. Currently, Pfizer offers an annual dividend yield of 7.32%, which is a semi-annual dividend amount of 43 cents per share ($1.72 a year). So, how can investors exploit its dividend yield to pocket a regular $500 monthly? To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $81,933 or around 3,488 shares. For a more modest $100 per month or $1,200 per year, you would need $16,396 or around 698 shares. To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($1.72 in this case). So, $6,000 / $1.72 = 3,488 ($500 per month), and $1,200 / $1.72 = 698 shares ($100 per month). View more earnings on PFE Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time. How that works: The dividend yield is computed by dividing the annual dividend payment by the stock's current price. For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40). Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield. PFE Price Action: Shares of Pfizer rose 0.9% to close at $23.49 on More: Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? PFIZER (PFE): Free Stock Analysis Report This article How To Earn $500 A Month From Pfizer Stock Ahead Of Q2 Earnings originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
How To Earn $500 A Month From Pfizer Stock Ahead Of Q2 Earnings
Pfizer Inc. (NYSE:PFE) will release earnings results for the second quarter before the opening bell on Tuesday, Aug. 5. Analysts expect the pharmaceutical company to report quarterly earnings of 57 cents per share, down from 60 cents per share in the year-ago period. Pfizer projects to report quarterly revenue of $13.53 billion, compared to $13.28 billion a year earlier, according to data from Benzinga Pro. Some investors may be eyeing potential gains from the company's dividends. Currently, Pfizer offers an annual dividend yield of 7.32%, which is a semi-annual dividend amount of 43 cents per share ($1.72 a year). So, how can investors exploit its dividend yield to pocket a regular $500 monthly? To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $81,933 or around 3,488 shares. For a more modest $100 per month or $1,200 per year, you would need $16,396 or around 698 shares. To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($1.72 in this case). So, $6,000 / $1.72 = 3,488 ($500 per month), and $1,200 / $1.72 = 698 shares ($100 per month). View more earnings on PFE Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time. How that works: The dividend yield is computed by dividing the annual dividend payment by the stock's current price. For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40). Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield. PFE Price Action: Shares of Pfizer rose 0.9% to close at $23.49 on More: Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? PFIZER (PFE): Free Stock Analysis Report This article How To Earn $500 A Month From Pfizer Stock Ahead Of Q2 Earnings originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
